Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZALENA: Lenalidomide + Azacitidine + DLI in Relapsed MDS/AML/CMML
NCT02472691Phase 2Completed
- Sponsor
- Heinrich Heine University Düsseldorf
- Start
- May 2015
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML), sponsored by Heinrich Heine University Düsseldorf. Started May 2015; status: completed.
02
Drugs
lenalidomide
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02472691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02472691.